In Brief: Alaris Medical
This article was originally published in The Gray Sheet
Executive Summary
Alaris Medical: San Diego-based infusion products firm says it is "proceeding with negotiations" regarding a dispute over its maquiladora manufacturing facilities in Tijuana, Mexico. The dispute is with Cal Pacifico, a Newport Beach, California contractor of maquiladora manufacturing services through which Alaris manufactures its products at two Tijuana plants under a "shelter" arrangement. Alaris says it notified Cal Pacifico in April that it would terminate the shelter program Aug. 1 and would take over its own manufacturing operation in Mexico. On June 11, five days after Alaris hired workers at the two plants, Cal Pacifico expelled all Alaris personnel from the facilities, thereby halting production. Alaris says it is ramping up manufacturing activities at its sites in San Diego, North Carolina, and Europe to address the shut down in Mexican operations and is "working diligently with Mexican authorities" to resume manufacturing in that country. The firm notes that it "does not anticipate that the dispute will have an impact on customers or results of its operations for the second quarter"...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.